Product logins

Find logins to all Clarivate products below.


chevron_left

Companies to Watch: Next Generation Gene Editing

What’s next for the field of gene editing
Startups, targets and indications driving the next generation of gene editing therapeutics

The FDA’s late-2023 approval of Casgevy™ and Lyfgenia™ for the treatment of sickle cell disease and beta thalassemia was a watershed event ushering in the age of gene editing therapeutics. What’s next for this burgeoning field of medical science?

Companies to Watch: Gene Editing will explore:

  • As-yet under-the-radar startups, and the targets and indications they are probing
  • Clinical, regulatory, market access and IP challenges that would-be entrants to the space must navigate
  • The potential impact of these therapeutics on regulators, payers, clinicians and patients

 

 

Related insights

The latest news, technologies, and resources from our team.

United States Urological Device Market United States Urological Device Market
United States Urological Device Market
United States Patient Monitoring Device Market United States Patient Monitoring Device Market
United States Patient Monitoring Device Market
Revolutionizing treatment: Opsynvi and Winrevair shake up the PAH market
chevron_left
chevron_right